Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

I agree with a lot of what you said except for the trials part. yes it is 3 to 4 years away from approval. But if you know most biotechs in phase 1 deal with only safety and that's it. What's unique with RXII is phase 1a and 1b act like a phase 2 because we actually just saw the efficacy for the single dose. If the multi dose comes out even more positive that reassure the technology even more.

The reasoning for the phase 2 is to go after keloids and advanced scars. While granted it is still risky, I think it is impressive the results we got yesterday for phase 1. Remember they only gave patients one injection of sd-rxRNA over 3 months. In 3 months it was able to reduce scarring significantly.